Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market 2024 - By Industry Analysis, Future Prediction, Business Overview And Forecast To 2033

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market size has grown rapidly in recent years. It will grow from $1.79 billion in 2023 to $1.98 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to emergence of antibiotic resistance, awareness campaigns and education, policy changes.

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market size is expected to see rapid growth in the next few years. It will grow to $3.00 billion in 2028 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to telemedicine and telehealth, personalized medicine approaches, point-of-care testing expansion, population health management strategies. Major trends in the forecast period include expansion of rapid point-of-care testing, personalized testing approaches, multi-disease testing platforms, community-based testing and outreach programs.

Market Overview -
Chlamydia trachomatis (CT) and Neisseria gonorrhea (NG) testing refers to the procedure for diagnosing sexually transmitted infections (STIs) brought on by Neisseria gonorrhea (NG) and chlamydia trachomatis (CT) within sexually active individuals, especially if they have multiple partners or engage in unprotected sexual activity. These tests are conducted to detect the presence of these bacteria in individuals, typically through methods such as urine samples, swabs of genital areas, or blood tests.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=14667&type=smp

Rising Incidence Of STIs Propels The Growth Of The CTNG Testing Market.
The increasing number of sexually transmitted infections (STIs) is expected to propel the growth of the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market going forward. Sexually transmitted infections (STIs) refer to diseases caused by infection with bacteria, viruses, or parasites that can be transmitted through sexual contact. STI rates are rising due to a lack of comprehensive sex education, increased sexual activity, stigma, and barriers. chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing is used for detecting and managing sexually transmitted infections (STIs) by enabling early diagnosis, treatment, and prevention of transmission. For instance, in July 2023, according to reports published by the World Health Organization, Switzerland, an intergovernmental organization, every day, more than 1 million sexually transmitted infections (STIs) are acquired worldwide, and every year, an estimated 374 million new infections occur with 1 of 4 treatable STIs. Therefore, there is an increasing number of sexually transmitted infections, which is driving the growth of the CTNG testing market.

Competitive Landscape -
Major companies operating in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers, Becton Dickinson and Company , Grifols SA, Hologic Inc., PerkinElmer, bioMérieux, Sysmex Corporation, Bio-Rad Laboratories, QIAGEN, Quidel Corporation, DiaSorin, Cepheid , Seegene Inc., Meridian Bioscience Inc., Sekisui Diagnostics, J. Mitra & Co. Pvt. Ltd., Atlas Medical, Hardy Diagnostics, Molbio Diagnostics Pvt. Ltd., NG Biotech

Innovative Solutions In The CT And NG Testing Market
Major companies operating in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market are focusing on the development of innovative testing solutions, such as BD COR MX/PX System, a high-throughput infectious disease molecular diagnostic platform, to address the need for accurate, efficient, and scalable testing methods to combat the increasing burden of sexually transmitted infections. BD COR MX/PX System is a sophisticated laboratory instrument or system designed to rapidly and efficiently analyze large numbers of samples for the presence of infectious agents. For instance, in May 2022, Becton Dickinson and Company, a US-based medical device company, launched its new, fully automated, high-throughput infectious disease molecular diagnostics platform called the BD COR MX/PX System, which is designed to streamline the workflow in large labs that process many infectious disease tests and such infections, including chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing. It automates the entire process using robotics and software algorithms, from receiving samples to delivering results. This can significantly improve efficiency and potentially reduce wait times for test results. Additionally, it features automation, high-throughput capability, dual DNA targets, and a modular and scalable design.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/chlamydia-trachomatis-ct-and-neisseria-gonorrhoeae-ng-testing-global-market-report

Key Segments -
The chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) testing market covered in this report is segmented -
1) By Test Type: Laboratory, Point Of Care Testing
2) By Product: Assays And Kits, Instruments Or Analyzers
3) By Technology: Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction, Immunodiagnostics, Other Technologies
4) By End User: Diagnostic Laboratories, Hospitals And Clinics, Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.